Galapagos misses on Phase 3 in Crohn's

 

• The two induction cohorts missed the co-primary endpoints of clinical remission and endoscopic response at Week 10

• In the maintenance phase, filgotinib 200mg once daily achieved the co-primary endpoints of clinical remission and endoscopic response at Week 58

• The safety findings were generally consistent with the known profile of filgotinib in rheumatoid arthritis (RA) and ulcerative colitis (UC)

• Galapagos decided not to submit a Marketing Authorization Application in Europe based on these topline data

• Galapagos remains fully committed to filgotinib, a JAK1 preferential inhibitor orally administered once daily, and its approved indications, RA and UC, and is on track to start a Phase 3 trial in axial spondyloarthritis (AxSpA) later this year

https://finance.yahoo.com/news/galapagos-announces-topline-results-phase-210100987.html